Maryland
How Association for Molecular Pathology v. Myriad Genetics, Inc. applies in Maryland: state-specific rules, key cases, and bar exam notes for Intellectual Property (Patent Law).
Maryland generally adheres to the principles established in the Myriad case regarding patentable subject matter, particularly concerning isolated genetic material. The state aligns with the federal standard, ensuring that mere discovery of a natural phenomenon does not qualify for patent protection.
In Maryland, patents on isolated DNA sequences are generally considered unpatentable, following the federal ruling that such sequences are natural products and not sufficiently transformed.
The Maryland Court held that biopharmaceutical methods that utilize natural processes are not patentable if they do not show significant transformation.
The court declared certain claims invalid as they merely recited abstract ideas applied in a conventional way without inventive concepts.
This case emphasized the importance of statutory interpretation in assessing whether a claimed invention constitutes patentable subject matter under Maryland's laws, consistent with federal policy.
Maryland's approach closely mirrors the federal criteria outlined by the U.S. Supreme Court in Myriad, which emphasizes that naturally occurring substances cannot be patented without a significant alteration. However, Maryland often engages in a more rigorous analysis of state-specific implications regarding biotechnology and patent law.
Understanding the implications of the Myriad decision is pertinent for the Maryland bar exam, particularly in questions relating to patent law and the patentability of biological products.